[Expression of secretory type II phospholipase A₂ in acute lung injury following acute pancreatitis and interventional effect of Qingyi decoction on it].

Article

Author: Zhao-hui Wang ; Xue-mei Zhang ; Hai-long Chen

OBJECTIVETo investigate the expression of secretory type II phospholipase A(2) (sPLA(2)-II) in lung of rats with acute lung injury (ALI) complicating severe acute pancreatitis (SAP), and the effect of Qingyi decoction (QYT) on ALI.METHODSThirty Sprague Dawley (SD) rats were randomly divided into three groups: sham operation (SO) group, model group and QYT group, with 10 rats in each group. SAP model was reproduced by reverse injection of sodium deoxycholate into the common bile- pancreatic duct of rats. The pancreas of rats was just exposed in SO group. QYT (10 ml/kg) was gavaged 30 minutes and 12 hours after SAP was induced in QYT group. The blood gas analysis was performed 24 hours after operation. Serum amylase (AMY) levels, sPLA(2) and lung wet/dry ratio (W/D) were determined. The sPLA(2)-II mRNA and sPLA(2)-II protein expression in lung were detected by reverse transcription- polymerase chain reaction (RT-PCR) and Western blotting. The pathological changes in lung and pancreas were observed.RESULTSCompared with SO group, the levels of arterial partial pressure of oxygen (PaO(2)) and pH value in model group were significantly decreased [PaO(2) (mm Hg, 1 mm Hg=0.133 kPa): 79.24±5.84 vs. 96.78±3.81, pH value: 7.269±0.054 vs. 7.391±0.054], arterial partial pressure of carbon dioxide (PaCO(2)), the serum levels of AMY, W/D ratio and the serum levels of sPLA(2) were significantly increased [PaCO(2) (mm Hg): 47.57±2.55 vs. 27.69±1.02, AMY (U/L): 7 144.19±727.91 vs. 1 193.41±192.54, W/D ratio: 8.57±2.45 vs. 3.70±0.90, sPLA(2) (nmol×min(-1) ×ml(-1)): 45.13±6.05 vs. 29.94±6.39], the expression of sPLA(2)-II mRNA (1.28±0.21 vs. 0.80±0.08) and protein were significantly increased (all P <0.05). Compared with model group, blood PaO(2) and pH value were significantly increased [PaO(2): (88.16±5.07) mm Hg, pH value: 7.322±0.039], the PaCO(2), the serum levels of AMY, W/D ratio and the serum levels of sPLA(2) in QYT group were significantly decreased [PaCO(2): (33.13±2.14) mm Hg, AMY: (4 283.51±527.52) U/L, W/D ratio: 4.05±0.52, sPLA(2): (28.00±4.78) nmol×min(-1) ×ml(-1)], and the expression of sPLA(2)-II mRNA (0.89±0.08) and protein were significantly decreased (all P <0.05). The pathological changes in lung and pancreas in QYT group were milder than those in SAP group.CONCLUSIONThe higher expression of sPLA(2)-IIin lung may be one of pathogenetic factors in ALI induced by SAP. Administration of QYT can reduce the injury of lung by decreasing the expression of sPLA(2)-II in transcriptional level and thus protecting pulmonary function.

01 Nov 2003·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Therapeutic effect of qingyi decoction and tetrandrine in treating severe acute pancreatitis in miniature pigs and serum drug level determination].

Article

Author: Dui, Dan-hua ; Li, Yong-yu ; Gao, Zhan-feng

OBJECTIVETo investigate the therapeutic effect of Qingyi Decoction (QYD) and tetrandrine (Tet), used singly or combind, in treating miniature pigs with severe acute pancreatitis (SAP) and its mechanism.METHODSThirty-two Guizhou miniature pigs were made into SAP model by pancreatic duct retrograde injection of 5% sodium taurocholate. They were randomly divided into 4 groups: the control group, the QYD group, the Tet group and the combined treated group. The serum amylase activity and interleukin-1 and 6 (IL-1, IL-6) contents in serum from vena cava and portal vein were tested by biochemistry and radioimmunoassay (RIA). Serum emodin and plasma Tet levels were measured by high performance liquid chromatography (HPLC) 24, 48 and 72 hrs after treatment. And the pathological changes of pancreas, lung and liver were observed under microscope.RESULTSThe mortality of SAP pigs was reduced significantly and the inflammatory injury of the organs was ameliorated obviously in all treated groups, and the increased amylase activity and IL-1, IL-6 levels was attenuated. The therapeutic effect was much more obvious, and the plasma Tet level at different time points were much higher in the combined treated group than those in the other two groups treated by single drug (P < 0.01).CONCLUSIONBoth QYD and Tet could treat effectively SAP through multiple pathways, combination of them reveals an elevation of serum drug concentration and shows a synergistic effect.

100 Deals associated with Qipi Decoction

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diarrhea	JP	Toyo-yakuko Co., Ltd	01 Oct 1987
Dyspepsia	JP	Toyo-yakuko Co., Ltd	01 Oct 1987
Gastroenteritis	JP	Toyo-yakuko Co., Ltd	01 Oct 1987

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Qipi Decoction

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation